What's on this Page
Flurandrenolide Brand Names
Cordran | Cordran SP | Cordran Tape | Nolix
What is Flurandrenolide
Flurandrenolide is a fluorinated, low- to medium-potency, topical corticosteroid. It is available in cream, lotion, ointment or impregnated tape formulation.
The impregnated tape is useful for occlusive therapy of small areas. Low potency products contain flurandrenolide in concentrations less than 0.25%. The drug is used for symptomatic treatment of corticosteroid-responsive skin disorders characterized by inflammation and/or pruritus such as seborrheic dermatitis, atopic dermatitis, and psoriasis.
Fluorinated corticosteroid compounds allow for treating affected areas with thicker skin such as the palms and soles.
Flurandrenolide application should be avoided, if possible, on areas of thinner skin, such as the face and intertriginous areas, because of potential toxicities inherent in fluorinated compounds.
Flurandrenolide was first approved by the FDA in 1963.
Indications
- alopecia
- atopic dermatitis
- contact dermatitis
- dermatitis
- discoid lupus erythematosus
- eczema
- exfoliative dermatitis
- granuloma annulare
- lichen planus
- lichen simplex
- pompholyx
- prurigo
- pruritus
- psoriasis
- Rhus dermatitis
- seborrheic dermatitis
- xerosis
Side Effects
- acneiform rash
- adrenocortical insufficiency
- cataracts
- contact dermatitis
- Cushing’s syndrome
- erythema
- folliculitis
- glycosuria
- growth inhibition
- headache
- hyperglycemia
- hypertension
- hypertrichosis
- hypothalamic-pituitary-adrenal (HPA) suppression
- impaired wound healing
- increased intracranial pressure
- infection
- maculopapular rash
- miliaria
- ocular hypertension
- papilledema
- pruritus
- pseudotumor cerebri
- purpura
- skin atrophy
- skin hypopigmentation
- skin irritation
- skin ulcer
- striae
- telangiectasia
- tolerance
- visual impairment
- withdrawal
- xerosis
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- acne rosacea
- acne vulgaris
- breast-feeding
- children
- Cushing’s syndrome
- diabetes mellitus
- fungal infection
- geriatric
- growth inhibition
- herpes infection
- hypothalamic-pituitary-adrenal (HPA) suppression
- increased intracranial pressure
- infants
- infection
- measles
- neonates
- occlusive dressing
- ocular exposure
- ophthalmic administration
- perioral dermatitis
- peripheral vascular disease
- pregnancy
- skin abrasion
- skin atrophy
- tuberculosis
- varicella
- viral infection
Interactions
- Metyrapone
Metyrapone: (Major) Medications which affect pituitary or adrenocortical function, including all corticosteroid therapy, should be discontinued prior to and during testing with metyrapone. Patients taking inadvertent doses of corticosteroids on the test day may exhibit abnormally high basal plasma cortisol levels and a decreased response to the test. Although systemic absorption of topical corticosteroids is minimal, temporary discontinuation of these products should be considered if possible to reduce the potential for interference with the test results.
